Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26406472 | 0.95 | GNAO1 (0.41) | GNAO1GNAI3GNAI1HRH3EPHX1 | |
| SCHEMBL21025868 | 0.84 | CYP2D6 (0.40) | GNAO1GNAI3GNAI1HRH3 | |
| SCHEMBL23695901 | 0.83 | KDM1A (0.32) | GNAO1GNAI3GNAI1HRH3KMT2A | |
| SCHEMBL23696220 | 0.82 | PRMT6 (0.36) | GNAO1GNAI3GNAI1HRH3KMT2A | |
| SCHEMBL18591791 | 0.80 | GBA2 (0.34) | GNAO1GNAI3GNAI1HRH3KMT2A | |
| SCHEMBL25831695 | 0.79 | GNAO1 (0.43) | GNAO1GNAI3GNAI1HRH3LTA4H | |
| SCHEMBL23696201 | 0.79 | KDM4E (0.32) | KMT2A | |
| SCHEMBL25727621 | 0.79 | KDM4E (0.32) | KMT2A | |
| SCHEMBL27013488 | 0.79 | PABPC1 (0.44) | GNAO1GNAI3GNAI1EPHX1EPHX2 | |
| SCHEMBL22790840 | 0.78 | GNAI3 (0.44) | GNAO1GNAI3GNAI1HRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.